Arnold L, Frauch P, Klöti A, Staub M
Novartis Pharma AG, Basel, Switzerland.
Pharm Acta Helv. 1998 Feb;72(6):327-32. doi: 10.1016/s0031-6865(97)00030-7.
Due to safety aspects, business risks and regulations of the FDA [FDA, 1983, Guide to Inspection of Computerized Systems in Drug Processing. USA] and the EU [EU-Leitfaden einer Guten Herstellpraxis for Arzneimittel, 1989, III/2244/87 Rev. 3. Jan. 1989], computer based systems used in the pharmaceutical production have to be validated. In this paper we assessed which modules of production planning and control (PPS) and production management systems (PMS) have to be validated using a risk analysis procedure. It could be shown that the necessity of the validation concerns, above all, the modules of production management systems. Furthermore, a software supplier questionnaire was developed according to the V-model of Royce [National Computing Centre, 1989. STARTS Publications, UK.]. The software supplier questionnaire was applied on four software products, which are mostly used in the pharmaceutical industry. Although these were developed according to a life cycle concept they fulfil the validation requirements, measured with the developed questionnaire, to a different degree. Especially the key element of the risk analysis was differently interpreted.
由于安全因素、商业风险以及美国食品药品监督管理局(FDA)[FDA,1983年,《药品加工计算机系统检查指南》,美国]和欧盟(EU)[《药品生产质量管理规范指南》,1989年,III/2244/87修订版,1989年1月]的相关规定,制药生产中使用的基于计算机的系统必须经过验证。在本文中,我们使用风险分析程序评估了生产计划与控制(PPS)和生产管理系统(PMS)的哪些模块需要进行验证。结果表明,验证的必要性首先涉及生产管理系统的模块。此外,根据罗伊斯的V模型[国家计算中心,1989年。STARTS出版物,英国]制定了一份软件供应商调查问卷。该软件供应商调查问卷应用于四种主要在制药行业使用的软件产品。尽管这些产品是根据生命周期概念开发的,但用所制定的调查问卷衡量,它们满足验证要求的程度各不相同。特别是对风险分析的关键要素有不同的解读。